Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA Sponsors Face Tight Controls On Meetings With US FDA After CR Letters

Dec 12 2018

• By Derrick Gingery

Clock numbers in close up — • Source: Susana Fernandez

Related Content

US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It

Oct 24 2017

Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says

Apr 15 2018

US FDA's Generics Program Reaches 'Steady State' Milestone

Sep 07 2018

ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says

Sep 10 2018

Additional Topics

United States Generic Drugs Drug Review Review Pathway Regulation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window